IQVIA Holdings Inc (IQV) is expected to report Q2 2026 revenue of $4.31 billion and adjusted EPS of $3.02, while currently trading at $209.41 relative to an average analyst price target of $236.12.
Investors are primarily focused on the Research & Development Solutions contracted backlog, which is anticipated to scale toward $34.5 billion as a bellwether for long-term clinical trial demand.
Following a robust start to the year, management is leaning on the newly launched IQVIA.ai platform to drive efficiencies and win market share in a stabilizing biopharma funding environment. Analysts are looking for continued acceleration in the Commercial Solutions segment to validate the company's recent guidance hike and confirm a recovery in the broader CRO sector.